All In Biotech

Drugs by condition

Drugs approved for cervical cancer

Brand-name prescription drugs and biologics whose FDA label lists cervical cancer as an approved use. Matched on the label phrases: "cervical cancer".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

10

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

5

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for cervical cancer.

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • Jobevne (Bevacizumab-Nwgd) · Biocon Biologics INC Apr 9, 2025
  • Vegzelma (Bevacizumab-Adcd) · Celltrion Sep 27, 2022
  • Alymsys (Bevacizumab-Maly) · Amneal Pharms LLC Apr 13, 2022
  • Tivdak (Tisotumab Vedotin-Tftv) · Seagen NovelAccelerated approvalPriority reviewSep 20, 2021

All approved drugs for cervical cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 3 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Vascular Endothelial Growth Factor Inhibitor (6)

  • Avastin Bevacizumab · Genentech · 2004
  • Jobevne Bevacizumab-Nwgd · Biocon Biologics INC · 2025
  • Vegzelma Bevacizumab-Adcd · Celltrion · 2022
  • Alymsys Bevacizumab-Maly · Amneal Pharms LLC · 2022
  • Zirabev Bevacizumab-Bvzr · Pfizer INC · 2019
  • Mvasi Bevacizumab-Awwb · Amgen INC · 2017

Endoglycosidase (1)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025

Programmed Death Receptor-1 Blocking Antibody (1)

  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014

Class not listed in FDA's data (2)

  • Tivdak Tisotumab Vedotin-Tftv · Seagen · 2021
  • Hycamtin Topotecan Hydrochloride · Sandoz · 1996

Drugs in development for cervical cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • ZimberelimabAB122, GS-0122Phase 312 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • 9MW2821Phase 311 trials

    Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • GEMPhase 35 trials

    Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer

  • SYS6002Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors

  • JSKN033Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors

  • WX390WXFL10030390Phase 33 trials

    Shanghai Jiatan Pharmatech Co., Ltd · Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Cervical Cancer Metastatic, Solid Tumor

  • BAT1308Recombinant humanized anti-PD-1 monoclonal antibodyPhase 32 trials

    Bio-Thera Solutions · Cervical Cancer, Advanced Solid Tumors

  • GLS-010Phase 32 trials

    Guangzhou Gloria Biosciences Co., Ltd. · Solid Tumor, Persistent, Recurrent, or Metastatic Cervical Cancer

  • LB1410Phase 32 trials

    L & L Bio Co., Ltd., Ningbo, China · Solid Tumor, Cervical Cancer

  • LB4330Phase 32 trials

    L & L Bio Co., Ltd., Ningbo, China · Solid Tumor, Cervical Cancer

  • XNW28012Phase 32 trials

    Evopoint Biosciences Inc. · Pancreatic Cancer, Advanced Solid Tumors, Pancreatic Carcinoma

  • Jiangsu HengRui Medicine Co., Ltd. · Cervical Cancer

More on cervical cancer: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.